Comment on Chandler et al. 23-Valent Pneumococcal Polysaccharide Vaccination Does Not Prevent Community-Acquired Pneumonia Hospitalizations Due to Vaccine-Type Streptococcus pneumoniae. Microorganisms 2022, 10, 560

The 23-valent pneumococcal polysaccharide vaccine (PPSV23) targets 23 common serotypes and is recommended for use in adults in various countries to protect against pneumococcal infection. Test-negative design (TND) studies aim to include cases and controls from the same healthcare facilities; howeve...

Descripción completa

Detalles Bibliográficos
Autores principales: Cossrow, Nicole, Joshi, Rennie, Klinker, Kenneth, Buchwald, Ulrike K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Comment
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9611352/
https://www.ncbi.nlm.nih.gov/pubmed/36296263
http://dx.doi.org/10.3390/microorganisms10101987
_version_ 1784819504554967040
author Cossrow, Nicole
Joshi, Rennie
Klinker, Kenneth
Buchwald, Ulrike K.
author_facet Cossrow, Nicole
Joshi, Rennie
Klinker, Kenneth
Buchwald, Ulrike K.
author_sort Cossrow, Nicole
collection PubMed
description The 23-valent pneumococcal polysaccharide vaccine (PPSV23) targets 23 common serotypes and is recommended for use in adults in various countries to protect against pneumococcal infection. Test-negative design (TND) studies aim to include cases and controls from the same healthcare facilities; however, design choices or limitations associated with conducting real-world research can affect the study results. Here, we highlight how some methodological limitations may have affected results and conclusions of a published study described by Chandler et al.
format Online
Article
Text
id pubmed-9611352
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96113522022-10-28 Comment on Chandler et al. 23-Valent Pneumococcal Polysaccharide Vaccination Does Not Prevent Community-Acquired Pneumonia Hospitalizations Due to Vaccine-Type Streptococcus pneumoniae. Microorganisms 2022, 10, 560 Cossrow, Nicole Joshi, Rennie Klinker, Kenneth Buchwald, Ulrike K. Microorganisms Comment The 23-valent pneumococcal polysaccharide vaccine (PPSV23) targets 23 common serotypes and is recommended for use in adults in various countries to protect against pneumococcal infection. Test-negative design (TND) studies aim to include cases and controls from the same healthcare facilities; however, design choices or limitations associated with conducting real-world research can affect the study results. Here, we highlight how some methodological limitations may have affected results and conclusions of a published study described by Chandler et al. MDPI 2022-10-08 /pmc/articles/PMC9611352/ /pubmed/36296263 http://dx.doi.org/10.3390/microorganisms10101987 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Comment
Cossrow, Nicole
Joshi, Rennie
Klinker, Kenneth
Buchwald, Ulrike K.
Comment on Chandler et al. 23-Valent Pneumococcal Polysaccharide Vaccination Does Not Prevent Community-Acquired Pneumonia Hospitalizations Due to Vaccine-Type Streptococcus pneumoniae. Microorganisms 2022, 10, 560
title Comment on Chandler et al. 23-Valent Pneumococcal Polysaccharide Vaccination Does Not Prevent Community-Acquired Pneumonia Hospitalizations Due to Vaccine-Type Streptococcus pneumoniae. Microorganisms 2022, 10, 560
title_full Comment on Chandler et al. 23-Valent Pneumococcal Polysaccharide Vaccination Does Not Prevent Community-Acquired Pneumonia Hospitalizations Due to Vaccine-Type Streptococcus pneumoniae. Microorganisms 2022, 10, 560
title_fullStr Comment on Chandler et al. 23-Valent Pneumococcal Polysaccharide Vaccination Does Not Prevent Community-Acquired Pneumonia Hospitalizations Due to Vaccine-Type Streptococcus pneumoniae. Microorganisms 2022, 10, 560
title_full_unstemmed Comment on Chandler et al. 23-Valent Pneumococcal Polysaccharide Vaccination Does Not Prevent Community-Acquired Pneumonia Hospitalizations Due to Vaccine-Type Streptococcus pneumoniae. Microorganisms 2022, 10, 560
title_short Comment on Chandler et al. 23-Valent Pneumococcal Polysaccharide Vaccination Does Not Prevent Community-Acquired Pneumonia Hospitalizations Due to Vaccine-Type Streptococcus pneumoniae. Microorganisms 2022, 10, 560
title_sort comment on chandler et al. 23-valent pneumococcal polysaccharide vaccination does not prevent community-acquired pneumonia hospitalizations due to vaccine-type streptococcus pneumoniae. microorganisms 2022, 10, 560
topic Comment
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9611352/
https://www.ncbi.nlm.nih.gov/pubmed/36296263
http://dx.doi.org/10.3390/microorganisms10101987
work_keys_str_mv AT cossrownicole commentonchandleretal23valentpneumococcalpolysaccharidevaccinationdoesnotpreventcommunityacquiredpneumoniahospitalizationsduetovaccinetypestreptococcuspneumoniaemicroorganisms202210560
AT joshirennie commentonchandleretal23valentpneumococcalpolysaccharidevaccinationdoesnotpreventcommunityacquiredpneumoniahospitalizationsduetovaccinetypestreptococcuspneumoniaemicroorganisms202210560
AT klinkerkenneth commentonchandleretal23valentpneumococcalpolysaccharidevaccinationdoesnotpreventcommunityacquiredpneumoniahospitalizationsduetovaccinetypestreptococcuspneumoniaemicroorganisms202210560
AT buchwaldulrikek commentonchandleretal23valentpneumococcalpolysaccharidevaccinationdoesnotpreventcommunityacquiredpneumoniahospitalizationsduetovaccinetypestreptococcuspneumoniaemicroorganisms202210560

Ejemplares similares